Insmed (INSM) News Today

Insmed Incorporated (NASDAQ: INSM) shares have risen, driven by overwhelmingly positive clinical data and a flurry of analyst price-target increases.

• Phase 2b PAH study of treprostinil palmitil inhalation powder (TPIP) met all primary and secondary endpoints, showing a 35% placebo-adjusted reduction in pulmonary vascular resistance and setting the stage for late-stage trials.
• Mizuho raised its price target to $110.00 with an “outperform” rating (12.2% upside).
• Royal Bank of Canada boosted its target to $106.00, maintaining an “outperform” rating (8.1% upside).
• Morgan Stanley increased its target to $102.00 and assigned an “overweight” rating (4.0% upside).
• Bank of America lifted its price target to $109.00 and reiterated a “buy” rating (11.2% upside).
• Wells Fargo & Company raised its target to $119.00 with an “overweight” rating (21.4% upside).
• HC Wainwright upped its price target to $120.00 and maintained a “buy” rating (22.5% upside).
• Leerink Partners set a new target of $115.00 with an “outperform” rating (17.4% upside).
• Cantor Fitzgerald updated its FY2026 EPS forecast to a loss of $4.24 per share (better than consensus of –$4.56) and kept an “overweight” rating.
• CEO Will Lewis discussed the positive trial results and outlook on CNBC’s “Fast Money.”
• Short-interest data showed no meaningful change, with a days-to-cover ratio remaining at 0.0.